A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.
An FDA advisory panel is reviewing Puma's breast cancer drug neratinib.
The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.
Amgen's osteoporosis setback will likely be seen as providing a commercial boost to Radius Health, which secured U.S. approval in April for a competing osteoporosis drug, Tymlos.
LJPC-501 reversed dangerously low blood pressure in patients suffering from a severe form of shock, but the drug did not improve total organ function or reduce mortality.
The new Incyte data revealed ahead of the ASCO meeting in June involve combination therapies with Merck and Bristol-Myers Squibb in multiple types of cancer.
The drug companies engineering T-cells to recognize and kill cancer, otherwise known as chimeric antigen receptor T-cells, or CAR-Ts, will be busy at the ASCO annual meeting in June.
The new Merck survival data were included in a research abstract for next month's American Society of Clinical Oncology (ASCO) annual meeting that was distributed on Wednesday night.
The new enasidenib data -- improved tumor response rate but shorter duration -- were made public on Wednesday night in a research abstract.
Monday's licensing deal is a nice win for Akebia because Fresenius is the largest dialysis provider in North America, serving approximately 40% of dialysis patients in the U.S.
The clinical trial shutdown ordered by regulators in its own country casts another shadow of doubt over AB Science at a most inopportune time.
XBiotech offered no reason for Thornburg's resignation, but he left two weeks after European regulators issued a preliminary recommendation to reject the application for the company's colon cancer drug Xilonix.
Keytruda is now the only PD-1 or PD-L1 checkpoint inhibitor approved to treat first-line lung cancer either as monotherapy or as part of a combination therapy.
Will the FDA revoke Roche's accelerated approval for Tecentriq in bladder cancer?
A presentation on May 18 will shed more light on the efficacy and safety of AB Science's ALS drug masitinib.
The death rattled Kite investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics.
The FDA wants 12-month endometrial safety data on TX-004HR. TherapeuticsMD conducted a single study that lasted just 12 weeks.
The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.
Zafgen is disclosing Thursday evening the first human data on ZGN-1061, with plans to move the obesity drug into a phase II study.
Some investors are disappointed with the timing of Clovis' ovarian cancer maintenance clinical trial.
Gilead's first-quarter conference call delivered another opportunity for analysts to ask management, 'Who are you going to buy and when?'
Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.
Today's Intra-Cellular update was probably going to send the stock price falling regardless of how management acted, but the refusal to be transparent made a bad day even worse.
Bryostatin failed to produce a meaningful improvement in dementia, cognition or memory of Alzheimer's patients.